Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human Thrombopoietin Antibodies:
anti-Mouse (Murine) Thrombopoietin Antibodies:
anti-Rat (Rattus) Thrombopoietin Antibodies:
Go to our pre-filtered search.
Human Monoclonal Thrombopoietin Primary Antibody for FACS, ELISA - ABIN969571
Graziano, Carone, Panza, Marino, Magini, Romeo, Pession, Seri: Association of hereditary thrombocythemia and distal limb defects with a thrombopoietin gene mutation. in Blood 2009
Show all 2 Pubmed References
Human Polyclonal Thrombopoietin Primary Antibody for IF (p), IHC (p) - ABIN1714401
Nakamura-Ishizu, Takubo, Kobayashi, Suzuki-Inoue, Suda: CLEC-2 in megakaryocytes is critical for maintenance of hematopoietic stem cells in the bone marrow. in The Journal of experimental medicine 2015
Dog (Canine) Polyclonal Thrombopoietin Primary Antibody for WB - ABIN2787808
Baker, Gray, Wright, Fitzsimons, Nimmo, Lowry, Mutrie,: The effect of a pedometer-based community walking intervention "Walking for Wellbeing in the West" on physical activity levels and health outcomes: a 12-week randomized controlled trial. in The international journal of behavioral nutrition and physical activity 2008
Show all 2 Pubmed References
These studies demonstrate that biallelic loss-of-function mutations in THPO cause bone marrow failure, which is unresponsive to transplant due to a hematopoietic cell-extrinsic mechanism.
Genetically engineered mesenchymal stromal cells produce IL-3 (show IL-3 Antibodies) and TPO to further improve human scaffold-based xenograft models
bone marrow megakaryocytes possess a complete mechanism to synthesize the ECM (show MMRN1 Antibodies) components, and that thrombopoietin is a pivotal regulator of this new function inducing transforming growth factor-b1 (TGF-beta1 (show TGFB1 Antibodies)) release and consequent activation of the downstream pathways, both in vitro and in vivo
High Thrombopoietin expression is associated with immune thrombocytopenia in pregnancy.
Colorectal cancer tumor-initiating cells (TICs) expressing CD110 (show MPL Antibodies), the thrombopoietin (TPO)-binding receptor, mediate liver metastasis. We show that TPO promotes metastasis of CD110 (show MPL Antibodies)+ TICs to the liver by activating lysine degradation.
decreased TPO levels or decreased bone marrow production of platelets may not be a cause of thrombocytopenia in chronic hepatitis C
WASP, RUNX1 (show RUNX1 Antibodies), and ANKRD26 (show ANKRD26 Antibodies) genes are important for normal TPO signaling and the network underlying thrombopoiesis.
Data suggest that elevated serum level of thrombopoietin may serve as unfavorable marker of stage of multiple myeloma.
The regulation of OCs by TPO highlights a novel therapeutic target for bone loss diseases and may be important to consider in the numerous hematologic disorders associated with alterations in TPO/c-mpl (show MPL Antibodies) signaling
TPO was greatly enhanced in HPT in comparison with ITP (show ITPA Antibodies) patients (958 +/- 659 and 11 +/- 27 pg/ml, p < 0.001). In the ITP (show ITPA Antibodies) group a reverse correlation was detected between TPO and glycocalicin (r = -0.373, p = 0.006).
Thrombopoietin-mediated phosphorylation of STAT5 (show STAT5A Antibodies) triggers its genome-wide relocation to STAT (show STAT1 Antibodies) consensus sites, resulting in loss of a uSTAT5 program that restrains megakaryocytic differentiation and activation of STAT5 (show STAT5A Antibodies)-driven gene expression.
Furthermore, although the contribution of the TPO treated graft to long-term hematological engraftment was reduced, the TPO treated and untreated grafts both contributed significantly to long-term chimerism in vivo.
TPO treatment also promoted the peripheral induction of Foxp3 (show FOXP3 Antibodies)(+) Tregs in conjunction with elevated circulating TGF-beta (show TGFB1 Antibodies) levels.
novel findings about aspects of TPO action on stem cells
Mpl (show MPL Antibodies) expression, but not Tpo, is fundamental in the development of JAK2V617F(+) myeloproliferative neoplasms
Thrombopoietin/MPL (show MPL Antibodies) signaling confers growth and survival capacity to CD41-positive cells in a mouse model of Evi1 (show MECOM Antibodies) leukemia.
Megakaryocytes regulate cell cycle quiescence of hematopoietic stem cell through the production of thrombopoietin.
IEX-1 (show IER3 Antibodies) has a role in activation of Erk (show EPHB2 Antibodies) and NF-kB pathways, which affects thrombopoietin-promoted NHEJ DNA repair in hematopoietic stem cells
Findings establish that Clock regulates Thpo and Mpl (show MPL Antibodies) expression in vivo, and demonstrate an important link between the body's circadian timing mechanisms and megakaryopoiesis.
Signal transduction pathway of ERK1/2 (show MAPK1/3 Antibodies) participates in the activation of thrombopoietin in inflammatory injury of BV2 (show DNAH9 Antibodies) cells.
The results demonstrate the possible involvement of locally produced TPO (show TPO Antibodies)/c-MPL (show MPL Antibodies) system as a 'physiological filter' in bovine ovary where they may promote cell selection by inducing proliferation of viable cells and scavenging non-viable cells.
These studies indicate that the functional role of Tpo in the differentiation of thrombocytes from hematopoietic stem and progenitor cells is well conserved among vertebrate organisms, positing the zebrafish as an excellent model to investigate diseases caused by dysregulated erythro- and thrombo-poietic differentiation.
Megakaryocytopoiesis is the cellular development process that leads to platelet production. The protein encoded by this gene is a humoral growth factor that is necessary for megakaryocyte proliferation and maturation, as well as for thrombopoiesis. This protein is the ligand for MLP/C_MPL, the product of myeloproliferative leukemia virus oncogene. Mutations in this gene are the cause of thrombocythemia 1. Alternate splicing results in multiple transcript variants of this gene.
, c-mpl ligand
, megakaryocyte colony-stimulating factor
, megakaryocyte growth and development factor
, megakaryocyte stimulating factor
, myeloproliferative leukemia virus oncogene ligand
, thrombopoietin nirs variant 1
, C-mpl ligand
, thrombopoietin (myeloproliferative leukemia virus oncogene ligand, megakaryocyte growth and development factor)